New avenues for anticoagulation in atrial fibrillation

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 68-77

  Mantha, S ^a   Cabral, K ^b   Ansell, J ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; GLYCOPROTEIN P INHIBITOR; MENADIONE EPOXIDE; PROTON PUMP INHIBITOR; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER METABOLISM; MORBIDITY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; HUMANS; SIGNAL TRANSDUCTION; STROKE;

EID: 84871276049     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.197     Document Type: Article

References (75)

1. Go, A.S. et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370-2375 (2001).
2. Heemstra, H.E., Nieuwlaat, R., Meijboom, M. & Crijns, H.J. The burden of atrial fibrillation in the Netherlands. Neth. Heart J. 19, 373-378 (2011).
3. Wolf, P.A., Abbott, R.D. & Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 22, 983-988 (1991).
4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154, 1449-1457 (1994).
5. You, J.J. et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e531S- e575S (2012).
6. Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M. & Palareti, G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e44S-e88S (2012).
7. Holbrook, A.M. et al. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165, 1095-1106 (2005).
8. Rosand, J., Eckman, M.H., Knudsen, K.A., Singer, D.E. & Greenberg, S.M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch. Intern. Med. 164, 880-884 (2004).
9. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N. Engl. J. Med. 323, 1505-1511 (1990).
10. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84, 527-539 (1991).
11. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet 343, 687-691 (1994).
12. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E.D. & Andersen, B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1, 175-179 (1989).
13. Hart, R.G., Pearce, L.A. & Aguilar, M.I. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
14. Ogilvie, I.M., Welner, S.A., Cowell, W. & Lip, G.Y. Ischaemic stroke and bleeding rates in "real-world" atrial fibrillation patients. Thromb. Haemost. 106, 34-44 (2011).
15. Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. & Radford, M.J. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
16. Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A. & Crijns, H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 137, 263-272 (2010).
17. Gage, B.F. et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 151, 713-719 (2006).
18. Apostolakis, S., Lane, D.A., Guo, Y., Buller, H. & Lip, G.Y. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation: The AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 60, 861-867 (2012).
19. Singer, D.E. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med. 151, 297-305 (2009).
20. Hart, R.G., Tonarelli, S.B. & Pearce, L.A. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke. 36, 1588-1593 (2005).
21. Singer, D.E. et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: The ATRIA study. Circ. Cardiovasc. Qual. Outcomes 2, 297-304 (2009).
22. Wilson, S.J. et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: A randomized controlled trial. CMAJ 169, 293-298 (2003).
23. Anderson, R.J. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J. Manag. Care Pharm. 10, 159-165 (2004).
24. Bauer, K.A. New anticoagulants: Anti IIa vs anti Xa-is one better? J. Thromb. Thrombolysis 21, 67-72 (2006).
25. Eriksson, B.I., Quinlan, D.J. & Weitz, J.I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin. Pharmacokinet. 48, 1-22 (2009).
26. Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386-399 (2008).
27. Kubitza, D., Becka, M., Wensing, G., Voith, B. & Zuehlsdorf, M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873-880 (2005).
28. Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 47, 285-295 (2008).
29. Alexander, J.H. & Singh, K.P. Inhibition of Factor Xa: A potential target for the development of new anticoagulants. Am. J. Cardiovasc. Drugs 5, 279-290 (2005).
30. Ufer, M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost. 103, 572-585 (2010).
31. Akins, P.T. et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: Pooled analysis of SPORTIF III and V clinical trials. Stroke 38, 874-880 (2007).
32. Lee, W.M. et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 28, 351-370 (2005).
33. Connolly, S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
34. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Reilly, P.A. & Wallentin, L. Newly identified events in the RE-LY trial. N. Engl. J. Med. 363, 1875-1876 (2010).
35. Wallentin, L. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 376, 975-983 (2010).
36. Hohnloser, S.H. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125, 669-676 (2012).
37. Uchino, K. & Hernandez, A.V. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. 172, 397-402 (2012).
38. Correia, L.C. & Lopes, A.A. Dabigatran and myocardial infarction: Metaillusion? Arch. Intern. Med. 172, 823; author reply 823 (2012).
39. Beasley, B.N., Unger, E.F. & Temple, R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med. 364, 1788-1790 (2011).
40. Patel, M.R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
41. Connolly, S.J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
42. Mantha, S. & Ansell, J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb. Haemost. 108, 476-484 (2012).
43. Lip, G.Y., Larsen, T.B., Skjøth, F. & Rasmussen, L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 60, 738-746 (2012).
44. Harenberg, J. et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int. Angiol. 31, 330-339 (2012).
45. Wann, L.S. et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 57, 1330-1337 (2011).
46. Skanes, A.C. et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28, 125-136 (2012).
47. US Food and Drug Administration. FDA drug safety communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate) . Accessed 29 August 2012
48. Rivaroxaban prescribing information. (2011). Accessed 29 August 2012
49. Eikelboom, J.W. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY trial. Circulation 123, 2363-2372 (2011).
50. Sullivan, S.D., Kreling, D.H. & Hazlet, T.K. Noncompliance with medication regimens and subsequent hospitalizations: A literature analysis and cost of hospitalization estimate. J. Res. Pharmaceut. Econ. 2, 19-33 (1990).
51. DiMatteo, M.R., Giordani, P.J., Lepper, H.S. & Croghan, T.W. Patient adherence and medical treatment outcomes: A meta-analysis. Med. Care 40, 794-811 (2002).
52. Cramer, J.A. Partial medication compliance: The enigma in poor medical outcomes. Am. J. Manag. Care 1, 167-74 (1995).
53. Claxton, A.J., Cramer, J. & Pierce, C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23, 1296(2001).
54. Yasuda, K., Lan, L.B., Sanglard, D., Furuya, K., Schuetz, J.D. & Schuetz, E.G. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J. Pharmacol. Exp. Ther. 303, 323-332 (2002).
55. Walenga, J.M. & Adiguzel, C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int. J. Clin. Pract. 64, 956-967 (2010).
56. Dabigatran prescribing information (2012). Accessed 6 September 2012
57. Nutescu, E., Chuatrisorn, I. & Hellenbart, E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J. Thromb. Thrombolysis 31, 326-343 (2011).
58. Mega, J.L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9-19 (2012).
59. Legrand, M. et al. The use of dabigatran in elderly patients. Arch. Intern. Med. 171, 1285-1286 (2011).
60. Cotton, B.A., McCarthy, J.J. & Holcomb, J.B. Acutely injured patients on dabigatran. N. Engl. J. Med. 365, 2039-2040 (2011).
61. Institute for Safe Medication Practices. Anticoagulants the leading reported drug risk in 2011 (2012). Accessed 31 August 2012
62. Gruber, A., Marzec, U.M., Buetehorn, U., Hanson, S. & Perzborn, E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. ASH Annual Meeting Abstracts 112, 3825 (2008).
63. van Ryn, J., Ruehl, D., Priepke, H., Hauel, N. & Wienen, W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or active prothrombin complex concentrate. Haematologica 93 (suppl. 1), Abs. 0370 (2008).
64. Zhou, W. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 42, 3594-3599 (2011).
65. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573-1579 (2011).
66. Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J.L. & Pernod, G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 108, 217-224 (2012).
67. Warkentin, T.E., Margetts, P., Connolly, S.J., Lamy, A., Ricci, C. & Eikelboom, J.W. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119, 2172-2174 (2012).
68. Garber, S.T., Sivakumar, W. & Schmidt, R.H. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J. Neurosurg. 116, 1093-1096 (2012).
69. Dager, W. & Roberts, A. Reversing dabigatran with FEIBA in a patient with a transseptal perforation during cardiac ablation. Crit Care Med 39 (suppl. 12), Abst. 867 (2011).
70. van Ryn, J. et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116-1127 (2010).
71. Wienen, W., Stassen, J.M., Priepke, H., Ries, U.J. & Hauel, N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb. Haemost. 98, 155-162 (2007).
72. Shah, S.V. & Gage, B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123, 2562-2570 (2011).
73. Go, A.S. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 290, 2685-2692 (2003).
74. Van Staa, T.P., Setakis, E., Di Tanna, G.L., Lane, D.A. & Lip, G.Y. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J. Thromb. Haemost. 9, 39-48 (2011).
75. DuBuske, L.M. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf. 28, 789-801 (2005).